keyword
MENU ▼
Read by QxMD icon Read
search

Martin Van den Bent

keyword
https://www.readbyqxmd.com/read/27686946/temozolomide-chemotherapy-versus-radiotherapy-in-high-risk-low-grade-glioma-eortc-22033-26033-a-randomised-open-label-phase-3-intergroup-study
#1
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, Andreas von Deimling, Thierry Gorlia, Khê Hoang-Xuan, Alba A Brandes, Guy Kantor, Martin J B Taphoorn, Mohamed Ben Hassel, Christian Hartmann, Gail Ryan, David Capper, Johan M Kros, Sebastian Kurscheid, Wolfgang Wick, Roelien Enting, Michele Reni, Brian Thiessen, Frederic Dhermain, Jacoline E Bromberg, Loic Feuvret, Jaap C Reijneveld, Olivier Chinot, Johanna M M Gijtenbeek, John P Rossiter, Nicolas Dif, Carmen Balana, Jose Bravo-Marques, Paul M Clement, Christine Marosi, Tzahala Tzuk-Shina, Robert A Nordal, Jeremy Rees, Denis Lacombe, Warren P Mason, Roger Stupp
BACKGROUND: Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide chemotherapy in patients with low-grade glioma, and assessed progression-free survival outcomes and identified predictive molecular factors. METHODS: For this randomised, open-label, phase 3 intergroup study (EORTC 22033-26033), undertaken in 78 clinical centres in 19 countries, we included patients aged 18 years or older who had a low-grade (WHO grade II) glioma (astrocytoma, oligoastrocytoma, or oligodendroglioma) with at least one high-risk feature (aged >40 years, progressive disease, tumour size >5 cm, tumour crossing the midline, or neurological symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any condition that could interfere with oral drug administration...
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27651472/seizure-control-as-a-new-metric-in-assessing-efficacy-of-tumor-treatment-in-low-grade-glioma-trials
#2
Edward K Avila, Marc Chamberlain, David Schiff, Jaap C Reijneveld, Terri S Armstrong, Roberta Ruda, Patrick Y Wen, Michael Weller, Johan A F Koekkoek, Sandeep Mittal, Yoshiki Arakawa, Ali Choucair, Jorge Gonzalez-Martinez, David R MacDonald, Ryo Nishikawa, Aashit Shah, Charles J Vecht, Paula Warren, Martin J van den Bent, Lisa M DeAngelis
Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy...
September 20, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27601076/functional-mechanisms-underlying-pleiotropic-risk-alleles-at-the-19p13-1-breast-ovarian-cancer-susceptibility-locus
#3
Kate Lawrenson, Siddhartha Kar, Karen McCue, Karoline Kuchenbaeker, Kyriaki Michailidou, Jonathan Tyrer, Jonathan Beesley, Susan J Ramus, Qiyuan Li, Melissa K Delgado, Janet M Lee, Kristiina Aittomäki, Irene L Andrulis, Hoda Anton-Culver, Volker Arndt, Banu K Arun, Brita Arver, Elisa V Bandera, Monica Barile, Rosa B Barkardottir, Daniel Barrowdale, Matthias W Beckmann, Javier Benitez, Andrew Berchuck, Maria Bisogna, Line Bjorge, Carl Blomqvist, William Blot, Natalia Bogdanova, Anders Bojesen, Stig E Bojesen, Manjeet K Bolla, Bernardo Bonanni, Anne-Lise Børresen-Dale, Hiltrud Brauch, Paul Brennan, Hermann Brenner, Fiona Bruinsma, Joan Brunet, Shaik Ahmad Buhari, Barbara Burwinkel, Ralf Butzow, Saundra S Buys, Qiuyin Cai, Trinidad Caldes, Ian Campbell, Rikki Canniotto, Jenny Chang-Claude, Jocelyne Chiquette, Ji-Yeob Choi, Kathleen B M Claes, Linda S Cook, Angela Cox, Daniel W Cramer, Simon S Cross, Cezary Cybulski, Kamila Czene, Mary B Daly, Francesca Damiola, Agnieszka Dansonka-Mieszkowska, Hatef Darabi, Joe Dennis, Peter Devilee, Orland Diez, Jennifer A Doherty, Susan M Domchek, Cecilia M Dorfling, Thilo Dörk, Martine Dumont, Hans Ehrencrona, Bent Ejlertsen, Steve Ellis, Christoph Engel, Eunjung Lee, D Gareth Evans, Peter A Fasching, Lidia Feliubadalo, Jonine Figueroa, Dieter Flesch-Janys, Olivia Fletcher, Henrik Flyger, Lenka Foretova, Florentia Fostira, William D Foulkes, Brooke L Fridley, Eitan Friedman, Debra Frost, Gaetana Gambino, Patricia A Ganz, Judy Garber, Montserrat García-Closas, Aleksandra Gentry-Maharaj, Maya Ghoussaini, Graham G Giles, Rosalind Glasspool, Andrew K Godwin, Mark S Goldberg, David E Goldgar, Anna González-Neira, Ellen L Goode, Marc T Goodman, Mark H Greene, Jacek Gronwald, Pascal Guénel, Christopher A Haiman, Per Hall, Emily Hallberg, Ute Hamann, Thomas V O Hansen, Patricia A Harrington, Mikael Hartman, Norhashimah Hassan, Sue Healey, Florian Heitz, Josef Herzog, Estrid Høgdall, Claus K Høgdall, Frans B L Hogervorst, Antoinette Hollestelle, John L Hopper, Peter J Hulick, Tomasz Huzarski, Evgeny N Imyanitov, Claudine Isaacs, Hidemi Ito, Anna Jakubowska, Ramunas Janavicius, Allan Jensen, Esther M John, Nichola Johnson, Maria Kabisch, Daehee Kang, Miroslav Kapuscinski, Beth Y Karlan, Sofia Khan, Lambertus A Kiemeney, Susanne Kruger Kjaer, Julia A Knight, Irene Konstantopoulou, Veli-Matti Kosma, Vessela Kristensen, Jolanta Kupryjanczyk, Ava Kwong, Miguel de la Hoya, Yael Laitman, Diether Lambrechts, Nhu Le, Kim De Leeneer, Jenny Lester, Douglas A Levine, Jingmei Li, Annika Lindblom, Jirong Long, Artitaya Lophatananon, Jennifer T Loud, Karen Lu, Jan Lubinski, Arto Mannermaa, Siranoush Manoukian, Loic Le Marchand, Sara Margolin, Frederik Marme, Leon F A G Massuger, Keitaro Matsuo, Sylvie Mazoyer, Lesley McGuffog, Catriona McLean, Iain McNeish, Alfons Meindl, Usha Menon, Arjen R Mensenkamp, Roger L Milne, Marco Montagna, Kirsten B Moysich, Kenneth Muir, Anna Marie Mulligan, Katherine L Nathanson, Roberta B Ness, Susan L Neuhausen, Heli Nevanlinna, Silje Nord, Robert L Nussbaum, Kunle Odunsi, Kenneth Offit, Edith Olah, Olufunmilayo I Olopade, Janet E Olson, Curtis Olswold, David O'Malley, Irene Orlow, Nick Orr, Ana Osorio, Sue Kyung Park, Celeste L Pearce, Tanja Pejovic, Paolo Peterlongo, Georg Pfeiler, Catherine M Phelan, Elizabeth M Poole, Katri Pylkäs, Paolo Radice, Johanna Rantala, Muhammad Usman Rashid, Gad Rennert, Valerie Rhenius, Kerstin Rhiem, Harvey A Risch, Gus Rodriguez, Mary Anne Rossing, Anja Rudolph, Helga B Salvesen, Suleeporn Sangrajrang, Elinor J Sawyer, Joellen M Schildkraut, Marjanka K Schmidt, Rita K Schmutzler, Thomas A Sellers, Caroline Seynaeve, Mitul Shah, Chen-Yang Shen, Xiao-Ou Shu, Weiva Sieh, Christian F Singer, Olga M Sinilnikova, Susan Slager, Honglin Song, Penny Soucy, Melissa C Southey, Marie Stenmark-Askmalm, Dominique Stoppa-Lyonnet, Christian Sutter, Anthony Swerdlow, Sandrine Tchatchou, Manuel R Teixeira, Soo H Teo, Kathryn L Terry, Mary Beth Terry, Mads Thomassen, Maria Grazia Tibiletti, Laima Tihomirova, Silvia Tognazzo, Amanda Ewart Toland, Ian Tomlinson, Diana Torres, Thérèse Truong, Chiu-Chen Tseng, Nadine Tung, Shelley S Tworoger, Celine Vachon, Ans M W van den Ouweland, Helena C van Doorn, Elizabeth J van Rensburg, Laura J Van't Veer, Adriaan Vanderstichele, Ignace Vergote, Joseph Vijai, Qin Wang, Shan Wang-Gohrke, Jeffrey N Weitzel, Nicolas Wentzensen, Alice S Whittemore, Hans Wildiers, Robert Winqvist, Anna H Wu, Drakoulis Yannoukakos, Sook-Yee Yoon, Jyh-Cherng Yu, Wei Zheng, Ying Zheng, Kum Kum Khanna, Jacques Simard, Alvaro N Monteiro, Juliet D French, Fergus J Couch, Matthew L Freedman, Douglas F Easton, Alison M Dunning, Paul D Pharoah, Stacey L Edwards, Georgia Chenevix-Trench, Antonis C Antoniou, Simon A Gayther
A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P=9.2 × 10(-20)), ER-negative BC (P=1.1 × 10(-13)), BRCA1-associated BC (P=7.7 × 10(-16)) and triple negative BC (P-diff=2 × 10(-5)). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P=2 × 10(-3)) and ABHD8 (P<2 × 10(-3))...
September 7, 2016: Nature Communications
https://www.readbyqxmd.com/read/27530779/treatment-of-secondary-central-nervous-system-lymphoma-with-intrathecal-rituximab-high-dose-methotrexate-and-r-dhap-followed-by-autologous-stem-cell-transplantation-results-of-the-hovon-80-phase-2-study
#4
Jeanette K Doorduijn, Gustaaf W van Imhoff, Bronno van der Holt, Harry C Schouten, Martijn R Schaafsma, Marius A MacKenzie, Joke W Baars, Marie José Kersten, Pieternella J Lugtenburg, Martin J van den Bent, Roelien H Enting, Fokje M Spoelstra, Philip Poortmans, Jacoline E C Bromberg
The prognosis of central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma is poor with 1-year survival historically at 0% to 20%. Aiming to improve these results, we performed a multicenter phase 2 study in patients with a CNS relapse, with or without concurrent systemic relapse. Treatment consisted of 2 cycles of R-DHAP alternating with high-dose methotrexate (MTX) and was combined with intrathecal rituximab. Responding patients received a third R-DHAP-MTX cycle followed by busulfan and cyclophosphamide myeloablative therapy and autologous stem cell transplantation...
August 17, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27461031/diagnostic-detection-of-allelic-losses-and-imbalances-by-next-generation-sequencing-1p-19q-co-deletion-analysis-of-gliomas
#5
Hendrikus J Dubbink, Peggy N Atmodimedjo, Ronald van Marion, Niels M G Krol, Peter H J Riegman, Johan M Kros, Martin J van den Bent, Winand N M Dinjens
Cancer cells are genomically unstable and accumulate tumor type-specific molecular aberrations, which may represent hallmarks for predicting prognosis and targets for therapy. Co-deletion of chromosomes 1p and 19q marks gliomas with an oligodendroglioma component and predicts a better prognosis and response to chemotherapy. In the current study, we present a novel method to detect chromosome 1p/19q co-deletion or loss of heterozygosity (LOH) in a diagnostic setting, based on single-nucleotide polymorphism (SNP) analysis and next-generation sequencing (NGS)...
September 2016: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/27459855/identification-of-independent-association-signals-and-putative-functional-variants-for-breast-cancer-risk-through-fine-scale-mapping-of-the-12p11-locus
#6
Chenjie Zeng, Xingyi Guo, Jirong Long, Karoline B Kuchenbaecker, Arnaud Droit, Kyriaki Michailidou, Maya Ghoussaini, Siddhartha Kar, Adam Freeman, John L Hopper, Roger L Milne, Manjeet K Bolla, Qin Wang, Joe Dennis, Simona Agata, Shahana Ahmed, Kristiina Aittomäki, Irene L Andrulis, Hoda Anton-Culver, Natalia N Antonenkova, Adalgeir Arason, Volker Arndt, Banu K Arun, Brita Arver, Francois Bacot, Daniel Barrowdale, Caroline Baynes, Alicia Beeghly-Fadiel, Javier Benitez, Marina Bermisheva, Carl Blomqvist, William J Blot, Natalia V Bogdanova, Stig E Bojesen, Bernardo Bonanni, Anne-Lise Borresen-Dale, Judith S Brand, Hiltrud Brauch, Paul Brennan, Hermann Brenner, Annegien Broeks, Thomas Brüning, Barbara Burwinkel, Saundra S Buys, Qiuyin Cai, Trinidad Caldes, Ian Campbell, Jane Carpenter, Jenny Chang-Claude, Ji-Yeob Choi, Kathleen B M Claes, Christine Clarke, Angela Cox, Simon S Cross, Kamila Czene, Mary B Daly, Miguel de la Hoya, Kim De Leeneer, Peter Devilee, Orland Diez, Susan M Domchek, Michele Doody, Cecilia M Dorfling, Thilo Dörk, Isabel Dos-Santos-Silva, Martine Dumont, Miriam Dwek, Bernd Dworniczak, Kathleen Egan, Ursula Eilber, Zakaria Einbeigi, Bent Ejlertsen, Steve Ellis, Debra Frost, Fiona Lalloo, Peter A Fasching, Jonine Figueroa, Henrik Flyger, Michael Friedlander, Eitan Friedman, Gaetana Gambino, Yu-Tang Gao, Judy Garber, Montserrat García-Closas, Andrea Gehrig, Francesca Damiola, Fabienne Lesueur, Sylvie Mazoyer, Dominique Stoppa-Lyonnet, Graham G Giles, Andrew K Godwin, David E Goldgar, Anna González-Neira, Mark H Greene, Pascal Guénel, Lothar Haeberle, Christopher A Haiman, Emily Hallberg, Ute Hamann, Thomas V O Hansen, Steven Hart, Jaana M Hartikainen, Mikael Hartman, Norhashimah Hassan, Sue Healey, Frans B L Hogervorst, Senno Verhoef, Carolyn B Hendricks, Peter Hillemanns, Antoinette Hollestelle, Peter J Hulick, David J Hunter, Evgeny N Imyanitov, Claudine Isaacs, Hidemi Ito, Anna Jakubowska, Ramunas Janavicius, Katarzyna Jaworska-Bieniek, Uffe Birk Jensen, Esther M John, Charles Joly Beauparlant, Michael Jones, Maria Kabisch, Daehee Kang, Beth Y Karlan, Saila Kauppila, Michael J Kerin, Sofia Khan, Elza Khusnutdinova, Julia A Knight, Irene Konstantopoulou, Peter Kraft, Ava Kwong, Yael Laitman, Diether Lambrechts, Conxi Lazaro, Loic Le Marchand, Chuen Neng Lee, Min Hyuk Lee, Jenny Lester, Jingmei Li, Annelie Liljegren, Annika Lindblom, Artitaya Lophatananon, Jan Lubinski, Phuong L Mai, Arto Mannermaa, Siranoush Manoukian, Sara Margolin, Frederik Marme, Keitaro Matsuo, Lesley McGuffog, Alfons Meindl, Florence Menegaux, Marco Montagna, Kenneth Muir, Anna Marie Mulligan, Katherine L Nathanson, Susan L Neuhausen, Heli Nevanlinna, Polly A Newcomb, Silje Nord, Robert L Nussbaum, Kenneth Offit, Edith Olah, Olufunmilayo I Olopade, Curtis Olswold, Ana Osorio, Laura Papi, Tjoung-Won Park-Simon, Ylva Paulsson-Karlsson, Stephanie Peeters, Bernard Peissel, Paolo Peterlongo, Julian Peto, Georg Pfeiler, Catherine M Phelan, Nadege Presneau, Paolo Radice, Nazneen Rahman, Susan J Ramus, Muhammad Usman Rashid, Gad Rennert, Kerstin Rhiem, Anja Rudolph, Ritu Salani, Suleeporn Sangrajrang, Elinor J Sawyer, Marjanka K Schmidt, Rita K Schmutzler, Minouk J Schoemaker, Peter Schürmann, Caroline Seynaeve, Chen-Yang Shen, Martha J Shrubsole, Xiao-Ou Shu, Alice Sigurdson, Christian F Singer, Susan Slager, Penny Soucy, Melissa Southey, Doris Steinemann, Anthony Swerdlow, Csilla I Szabo, Sandrine Tchatchou, Manuel R Teixeira, Soo H Teo, Mary Beth Terry, Daniel C Tessier, Alex Teulé, Mads Thomassen, Laima Tihomirova, Marc Tischkowitz, Amanda E Toland, Nadine Tung, Clare Turnbull, Ans M W van den Ouweland, Elizabeth J van Rensburg, David Ven den Berg, Joseph Vijai, Shan Wang-Gohrke, Jeffrey N Weitzel, Alice S Whittemore, Robert Winqvist, Tien Y Wong, Anna H Wu, Drakoulis Yannoukakos, Jyh-Cherng Yu, Paul D P Pharoah, Per Hall, Georgia Chenevix-Trench, Alison M Dunning, Jacques Simard, Fergus J Couch, Antonis C Antoniou, Douglas F Easton, Wei Zheng
BACKGROUND: Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk. METHOD: We performed a fine-scale mapping study of a 700 kb region including 441 genotyped and more than 1300 imputed genetic variants in 48,155 cases and 43,612 controls of European descent, 6269 cases and 6624 controls of East Asian descent and 1116 cases and 932 controls of African descent in the Breast Cancer Association Consortium (BCAC; http://bcac...
June 21, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27396951/a-validated-microrna-profile-with-predictive-potential-in-glioblastoma-patients-treated-with-bevacizumab
#7
Josie Hayes, Helene Thygesen, Walter Gregory, David R Westhead, Pim J French, Martin J Van Den Bent, Sean E Lawler, Susan C Short
PURPOSE: We investigated whether microRNA expression data from glioblastoma could be used to produce a profile that defines a bevacizumab responsive group of patients. PATIENTS AND METHODS: TCGA microRNA expression data from tumors resected at first diagnosis of glioblastoma in patients treated with bevacizumab at any time during the course of their disease were randomly separated into training (n = 50) and test (n = 37) groups for model generation. MicroRNA-seq data for 51 patients whose treatment included bevacizumab in the BELOB trial were used as an independent validation cohort...
October 2016: Molecular Oncology
https://www.readbyqxmd.com/read/27317657/recording-analysis-and-interpretation-of-spreading-depolarizations-in-neurointensive-care-review-and-recommendations-of-the-cosbid-research-group
#8
Jens P Dreier, Martin Fabricius, Cenk Ayata, Oliver W Sakowitz, C William Shuttleworth, Christian Dohmen, Rudolf Graf, Peter Vajkoczy, Raimund Helbok, Michiyasu Suzuki, Alois J Schiefecker, Sebastian Major, Maren Kl Winkler, Eun-Jeung Kang, Denny Milakara, Ana I Oliveira-Ferreira, Clemens Reiffurth, Gajanan S Revankar, Kazutaka Sugimoto, Nora F Dengler, Nils Hecht, Brandon Foreman, Bart Feyen, Daniel Kondziella, Christian K Friberg, Henning Piilgaard, Eric S Rosenthal, M Brandon Westover, Anna Maslarova, Edgar Santos, Daniel Hertle, Renán Sánchez-Porras, Sharon L Jewell, Baptiste Balança, Johannes Platz, Jason M Hinzman, Janos Lückl, Karl Schoknecht, Michael Schöll, Christoph Drenckhahn, Delphine Feuerstein, Nina Eriksen, Viktor Horst, Julia S Bretz, Paul Jahnke, Michael Scheel, Georg Bohner, Egill Rostrup, Bente Pakkenberg, Uwe Heinemann, Jan Claassen, Andrew P Carlson, Christina M Kowoll, Svetlana Lublinsky, Yoash Chassidim, Ilan Shelef, Alon Friedman, Gerrit Brinker, Michael Reiner, Sergei A Kirov, R David Andrew, Eszter Farkas, Erdem Güresir, Hartmut Vatter, Lee S Chung, K C Brennan, Thomas Lieutaud, Stephane Marinesco, Andrew Ir Maas, Juan Sahuquillo, Markus A Dahlem, Frank Richter, Oscar Herreras, Martyn G Boutelle, David O Okonkwo, M Ross Bullock, Otto W Witte, Peter Martus, Arn Mjm van den Maagdenberg, Michel D Ferrari, Rick M Dijkhuizen, Lori A Shutter, Norberto Andaluz, André P Schulte, Brian MacVicar, Tomas Watanabe, Johannes Woitzik, Martin Lauritzen, Anthony J Strong, Jed A Hartings
Spreading depolarizations (SD) are waves of abrupt, near-complete breakdown of neuronal transmembrane ion gradients, are the largest possible pathophysiologic disruption of viable cerebral gray matter, and are a crucial mechanism of lesion development. Spreading depolarizations are increasingly recorded during multimodal neuromonitoring in neurocritical care as a causal biomarker providing a diagnostic summary measure of metabolic failure and excitotoxic injury. Focal ischemia causes spreading depolarization within minutes...
June 17, 2016: Journal of Cerebral Blood Flow and Metabolism
https://www.readbyqxmd.com/read/27238144/gene-tailored-treatments-for-brain-disorders-challenges-and-opportunities
#9
Giovanni Esposito, Jean Marc Burgunder, John Dunlop, Philip Gorwood, Amir Inamdar, Stefan M Pfister, Roland Pochet, Martin J van den Bent, Nancy Van Hoylandt, Michael Weller, Manfred Westphal, Wolfgang Wick, David Nutt
Brain disorders pose major challenges to medicine and treatment innovation. This is because their spectrum spans inflammatory, degenerative, traumatic/ischaemic, and neoplastic disease processes with a complex and often ill- understood aetiology. An improved genetic and genomic understanding of specific disease pathways offers new approaches to these challenges, but at present it is in its infancy. Here, we review different aspects of the challenges facing neuromedicine, give examples of where there are advances, and highlight challenges to be overcome...
2016: Public Health Genomics
https://www.readbyqxmd.com/read/27143690/phase-ii-study-of-radiotherapy-and-temsirolimus-versus-radiochemotherapy-with-temozolomide-in-patients-with-newly-diagnosed-glioblastoma-without-mgmt-promoter-hypermethylation-eortc-26082
#10
Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J van den Bent, Martin J B Taphoorn, Jonathan Steuve, Alba A Brandes, Marie-France Hamou, Antje Wick, Markus Kosch, Michael Weller, Roger Stupp, Patrick Roth, Vassilis Golfinopoulos, Jean-Sebastien Frenel, Mario Campone, Damien Ricard, Christine Marosi, Salvador Villa, Astrid Weyerbrock, Kirsten Hopkins, Krisztian Homicsko, Benoit Lhermitte, Gianfranco Angelo Pesce, Monika E Hegi
PURPOSE: EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methlyguanine-DNA-methlytransferase (MGMT) promoter. PATIENTS AND METHODS: Patients (n=257) fulfilling eligibility criteria underwent central MGMT testing. Patients with MGMT unmethylated glioblastoma (n=111) were randomized 1:1 between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly temsirolimus (25 mg)...
May 3, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/26948366/low-grade-and-anaplastic-oligodendroglioma
#11
Martin J Van Den Bent, Jacolien E C Bromberg, Jan Buckner
Anaplastic oligodendrogliomas have long attracted interest because of their sensitivity to chemotherapy, in particular in the subset of 1p/19q co-deleted tumors. Recent molecular studies have shown that all 1p/19q co-deleted tumors have IDH mutations and most of them also have TERT mutations. Because of the presence of similar typical genetic alterations in astrocytoma and glioblastoma, the current trend is to diagnose these tumors on the basis of their molecular profile. Further long-term follow-up analysis of both EORTC and RTOG randomized studies on (neo)adjuvant procarbazine, lomustine, vincristine (PCV) chemotherapy have shown that adjuvant chemotherapy indeed improves outcome, and this is now standard of care...
2016: Handbook of Clinical Neurology
https://www.readbyqxmd.com/read/26762204/identification-of-patients-with-recurrent-glioblastoma-who-may-benefit-from-combined-bevacizumab-and-ccnu-therapy-a-report-from-the-belob-trial
#12
RANDOMIZED CONTROLLED TRIAL
Lale Erdem-Eraslan, Martin J van den Bent, Youri Hoogstrate, Hina Naz-Khan, Andrew Stubbs, Peter van der Spek, René Böttcher, Ya Gao, Maurice de Wit, Walter Taal, Hendrika M Oosterkamp, Annemiek Walenkamp, Laurens V Beerepoot, Monique C J Hanse, Jan Buter, Aafke H Honkoop, Bronno van der Holt, René M Vernhout, Peter A E Sillevis Smitt, Johan M Kros, Pim J French
The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM). In this study, we performed gene expression profiling (DASL and RNA-seq) of formalin-fixed, paraffin-embedded tumor material from participants of the BELOB trial to identify patients with recurrent GBM who benefitted most from beva+CCNU treatment. We demonstrate that tumors assigned to the IGS-18 or "classical" subtype and treated with beva+CCNU showed a significant benefit in progression-free survival and a trend toward benefit in overall survival, whereas other subtypes did not exhibit such benefit...
February 1, 2016: Cancer Research
https://www.readbyqxmd.com/read/26699864/pi3-kinase-mutations-and-mutational-load-as-poor-prognostic-markers-in-diffuse-glioma-patients
#13
Kaspar Draaisma, Maarten M J Wijnenga, Bas Weenink, Ya Gao, Marcel Smid, P Robe, Martin J van den Bent, Pim J French
INTRODUCTION: Recent advances in molecular diagnostics allow diffuse gliomas to be classified based on their genetic changes into distinct prognostic subtypes. However, a systematic analysis of all molecular markers has thus far not been performed; most classification schemes use a predefined and select set of genes/molecular markers. Here, we have analysed the TCGA dataset (combined glioblastoma (GBM) and lower grade glioma (LGG) datasets) to identify all prognostic genetic markers in diffuse gliomas in order to generate a comprehensive classification scheme...
2015: Acta Neuropathologica Communications
https://www.readbyqxmd.com/read/26572593/oligodendrogliomas-a-short-history-of-clinical-developments
#14
Martin J van den Bent
No abstract text is available yet for this article.
2015: CNS Oncology
https://www.readbyqxmd.com/read/26397230/chemotherapy-for-low-grade-glioma-when-for-whom-which-regimen
#15
REVIEW
Martin J van den Bent
PURPOSE OF REVIEW: The role of chemotherapy in low-grade glioma has been redefined with the long-term follow-up of the RTOG 9802, which investigated adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in addition to radiotherapy, and the results of EORTC trial 22033 in a similar patient population that compared temozolomide to radiotherapy. RECENT FINDINGS: RTOG 9802 trial showed an increase in overall survival after adjuvant chemotherapy. Median overall survival increased from 7...
December 2015: Current Opinion in Neurology
https://www.readbyqxmd.com/read/26354927/molecular-classification-of-anaplastic-oligodendroglioma-using-next-generation-sequencing-a-report-of-the-prospective-randomized-eortc-brain-tumor-group-26951-phase-iii-trial
#16
Hendrikus J Dubbink, Peggy N Atmodimedjo, Johan M Kros, Pim J French, Marc Sanson, Ahmed Idbaih, Pieter Wesseling, Roelien Enting, Wim Spliet, Cees Tijssen, Winand N M Dinjens, Thierry Gorlia, Martin J van den Bent
BACKGROUND: Histopathological diagnosis of diffuse gliomas is subject to interobserver variation and correlates modestly with major prognostic and predictive molecular abnormalities. We investigated a series of patients with locally diagnosed anaplastic oligodendroglial tumors included in the EORTC phase III trial 26951 on procarbazine/lomustine/vincristine (PCV) chemotherapy to explore the diagnostic, prognostic, and predictive value of targeted next-generation sequencing (NGS) in diffuse glioma and to assess the prognostic impact of FUBP1 and CIC mutations...
March 2016: Neuro-oncology
https://www.readbyqxmd.com/read/26250565/consensus-recommendations-for-a-standardized-brain-tumor-imaging-protocol-in-clinical-trials
#17
REVIEW
Benjamin M Ellingson, Martin Bendszus, Jerrold Boxerman, Daniel Barboriak, Bradley J Erickson, Marion Smits, Sarah J Nelson, Elizabeth Gerstner, Brian Alexander, Gregory Goldmacher, Wolfgang Wick, Michael Vogelbaum, Michael Weller, Evanthia Galanis, Jayashree Kalpathy-Cramer, Lalitha Shankar, Paula Jacobs, Whitney B Pope, Dewen Yang, Caroline Chung, Michael V Knopp, Soonme Cha, Martin J van den Bent, Susan Chang, W K Al Yung, Timothy F Cloughesy, Patrick Y Wen, Mark R Gilbert
A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials...
September 2015: Neuro-oncology
https://www.readbyqxmd.com/read/26065612/response-assessment-criteria-for-brain-metastases-proposal-from-the-rano-group
#18
REVIEW
Nancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, Igor J Barani, Daniel P Barboriak, Brigitta G Baumert, Martin Bendszus, Paul D Brown, D Ross Camidge, Susan M Chang, Janet Dancey, Elisabeth G E de Vries, Laurie E Gaspar, Gordon J Harris, F Stephen Hodi, Steven N Kalkanis, Mark E Linskey, David R Macdonald, Kim Margolin, Minesh P Mehta, David Schiff, Riccardo Soffietti, John H Suh, Martin J van den Bent, Michael A Vogelbaum, Patrick Y Wen
CNS metastases are the most common cause of malignant brain tumours in adults. Historically, patients with brain metastases have been excluded from most clinical trials, but their inclusion is now becoming more common. The medical literature is difficult to interpret because of substantial variation in the response and progression criteria used across clinical trials. The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary effort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases...
June 2015: Lancet Oncology
https://www.readbyqxmd.com/read/25994416/assessment-methods-and-prevalence-of-cognitive-dysfunction-in-patients-with-low-grade-glioma-a-systematic-review
#19
REVIEW
Ellen M P van Loon, Majanka H Heijenbrok-Kal, Wouter S van Loon, Martin J van den Bent, Arnaud J P E Vincent, Inge de Koning, Gerard M Ribbers
OBJECTIVE: To systematically review the literature for studies on cognitive functioning in patients with low-grade glioma to evaluate assessment methods and prevalence of cognitive dysfunction. DATA SOURCES: A search was made in PubMed, Embase, and PsycINFO for articles published between January 2002 and June 2012 using cognition, memory, attention, executive functioning, and low-grade glioma as search terms. STUDY SELECTION: Two reviewers independently performed the study selection and data extraction...
June 2015: Journal of Rehabilitation Medicine
https://www.readbyqxmd.com/read/25986504/neuro-oncology-the-many-challenges-of-treating-elderly-glioblastoma-patients
#20
COMMENT
Martin J van den Bent, Jacoline E Bromberg
No abstract text is available yet for this article.
July 2015: Nature Reviews. Neurology
keyword
keyword
90962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"